normal saline solution for infusion, Ociperlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tislelizumab, Ociperlimab
BGB-A317-A1217-302
Phase 3 small_molecule active
Quick answer
normal saline solution for infusion, Ociperlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tislelizumab, Ociperlimab for Locally advanced, unresectable, or metastatic non small cell lung cancer is a Phase 3 program (small_molecule) at BeiGene Ireland Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeiGene Ireland Ltd
- Indication
- Locally advanced, unresectable, or metastatic non small cell lung cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active